| My Bounce Play for Wednesday is: XUII Xumanii(TM) (XUII) ? XUII exploded out of the gates Tuesday morning hitting an intra-day high of $0.754 representing 214% Gains from my initial alert at $0.24!!!.... Then late in the day we witnessed heavy profit taking and XUII closed down 44% on 65,863,056 and that's not a miss print that's 65,863,056 shares traded!! ? Now This Is EXTREMLY IMPORTANT To Pay Close ATTENTION!! -----------------------------------------------------------------------------
Make Sure You're Watching XUII At Wednesday's Open!!
----------------------------------------------------------------------------- ?? Symbol: XUII
Co. Name: Xumanii(TM)
Tuesday's Closing Price: $0.3721 ? I love BEATEN DOWN stocks... Some of our best trades have been from stocks that have been severely over sold and then Bounce Hard! ? We have witnessed many stocks fall hard and BOUNCE BACK even faster in the past, so keep a close eye on XUII! ? XUII could turn out to be one of the best Bounce Plays we see this summer! BUT REMEMBER, at the same time it could be VERY RISKY! ?? Make Sure XUII Is On Your RADAR! ? Happy Trading!! The OTCtipReporter Team ? DONT MISS ANOTHER HOT OPPORTUNITY TO MAKE
HUGE PROFITS!
?
? ? ? ? ? ? ? ? ? ? ? ? ? ? GENERAL NOTICE AND DISCLAIMER - PLEASE READ CAREFULLY
The companies that are discussed on OTCtipReporter.com have not approved the statements made. This opinion contains forward-looking statements that involve risks and uncertainties. A company's actual results could differ materially from those described in any forward-looking statements or announcements discussed herein. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. OTCtipReporter.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Nor are any of its officers, affiliates, or employees. Please consult a broker before purchasing or selling any securities viewed on OTCtipReporter.com or mentioned herein. Affiliates, officers, directors and employees of OTCtipReporter.com may have also bought or may buy shares of companies mentioned herein and may profit in the event those shares rise in value. OTCtipReporter.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make their own decision based on his or her judgment of the market. This advertisement is not a solicitation or recommendation to buy, sell or hold securities and does not provide an analysis of the financial position of the company. We recommend you use the information found in this advertisement as an initial starting point for conducting your own research on the advertised company in order to determine your own personal opinion of the company before investing. All statements and opinions contained in this advertisement are the sole opinion of the authors and are subject to change without notice. We are not liable for any investment decisions by our readers. Readers should independently investigate and fully understand all risks before investing. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser or broker prior to completing any such purchase or sale decision. We are not registered investment advisers, or broker-dealers, or members of any financial regulatory bodies. Furthermore, our associates and/or employees and/or principals may have stock positions in advertised companies purchased in the open market or in private transactions. These positions may be liquidated, without prior notification, even after we have made positive comments regarding the advertised company. The receipt of this information constitutes your acceptance of these terms and conditions. Reading this advertisement shall not create under any circumstances an offer to buy or sell stock in any company advertised. Nor shall it create any principal-agent relationship between the reader and us. Void where prohibited. Information within this advertisement contains "forward looking" statements within the meaning of Section-27(a) of the U.S. Securities Act-of-1933 and Section 21(e) of the U.S. Securities Exchange Act-of -934. Neither OTCtipReporter.com, its officers, affiliates, or employees is a broker-dealer. The information on OTCtipReporter.com, including the opinions expressed and the statements made within, is for informational and advertising purposes only and should not be construed as investment-advice, and does not constitute an offer to sell any securities, nor is it to be construed as a solicitation to purchase any securities in any state or other jurisdiction where the offer or sale is not permitted. The information to prepare this report is believed to be from reliable sources, but no representation is made as to the accuracy or completeness of such information. Investment in securities carries a high degree of risk and involves risks and uncertainties, which may result in investors losing all of their invested capital. Past performance does not guarantee future results. The information contained herein contains "forward-looking statements," within the meaning of Section-27A of the Securities Act-of-1933 and Section 21E of the Securities Exchange Act-of-1934. Forward-looking statements are based upon expectations, estimates and projections at the time the statements are made and involve risks and uncertainties that could cause actual events to differ materially from those anticipated. Forward-looking statements may be identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should, or might occur. Any statements that express or involve predictions, expectations, beliefs, plans, projections, objectives, goals or future events or performance may be forward-looking statements. Factors that could cause actual results to differ materially include but are not limited to adverse economic conditions, intense competition, lack of meaningful research results, inadequate capital, termination of contracts or agreements, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other key personnel, and other risks detailed in the reports filed with the Securities and Exchange Commission by the companies who are mentioned in this periodical. Readers should consult with their own professional investment, tax and portfolio advisors before making any investment decision and should independently verify all information herein. More complete information about any of the companies mentioned in this periodical is available from the website of the Securities and Exchange Commission, at sec.gov, and copies of their filings may be read without charge and copies obtained at prescribed rates from the public reference facilities of the Commission, at 450 Fifth Street, NW, Washington, DC 20549. ? Buying and Selling of Shares OTCtipReporter.com intends to sell its shares. OTCtipReporter.com may sell its shares for less than target prices given in opinions. OTCtipReporter.com affiliates, officers, directors and employees may have also bought or may buy the shares discussed in this report and may profit in the event those shares rise in value. OTCtipReporter.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. There are risks involved Always remember that OTCtipReporter.com are not analysts and investing in securities such as the ones listed within are for high risk tolerant individuals only and not the general public. Whether you are an experienced investor or not you should always consult with a broker before purchasing or selling any securities viewed on OTCtipReporter.com. If at any time you wish to be removed from our list simply unsubscribe in any of the previous emails sent to you. ? 17(B) DISCLAIMER www.OTCTipReporter.com is owned and operated by LionsGate Ventures Inc.. LionsGate Ventures Inc. and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as "OTC" or "we" or "us" or "our). OTC electronically disseminates information (the "Information") on its website, in newsletters, featured reports, spam compliant double-opt in email communications or otherwise pertaining to Profiled Companies' (the "Issuer" or "Issuers" or "Profiled Company" or "Profiled Companies"), the securities of which are most frequently common stock shares quoted on the Over the Counter Bulletin Board ("OTCBB") or Pink Sheets. The Information is based on information received from Issuers, publicly available information, such as quarterly (with unaudited financial statements) and annual reports (with audited financial statements) filed with the Securities and Exchange Commission ("SEC"), quarterly and annual unaudited financial reports and Information and Disclosure Statements filed with the Pink Sheets, the Issuer's website and information obtained through search engines such as Yahoo Finance, Market Watch and Business Wire. We synthesize the Information from these informational sources for our Readers as a starting point for further inquiry into the Issuer and its securities. Because OTC receives compensation for OTC's dissemination of the Information (as disclosed in our Compensation Disclosure Section), including at times in the form of common stock shares (the "Shares"), OTC should not be considered to be an independent provider of the Information. OTC is not a research analyst, registered investment advisor or registered securities broker dealer and the Information should not be construed in any manner, shape or form as investment-advice, investment recommendations or opinions or viewpoints regarding the Profiled Company or its securities or as a solicitation to offer, purchase or sell the Profiled Company's securities. OTC does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information and conducts no due diligence whatsoever of the Profiled Companies. Because the Information is presented on an "as is" basis, your use of the Information is at your own risk. OTC disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is accurate or reliable or free of errors. By reading the Information, the Reader hereby agrees to indemnify and hold OTC harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to the Information. Statements contained in the Information that are not historical facts are forward looking statements that involve risks and uncertainties as indicated by words such as "believes", "expects", "estimates", "may", "will" or "should" or "anticipates" or similar expressions. These forward looking statements may materially differ from the Issuer's actual operational and financial results or its actual achievements, claimed or otherwise. OTC does not undertake any responsibility whatsoever of these forward looking statements, nor any legal obligation whatsoever of updating the Information. The Information is presented only as a brief "snapshot" of the Profiled Company and should only be used, at most, and if at all, as a starting point for Readers to conduct a thorough investigation of the Profiled Company and its securities, to consult with their financial, legal or other advisor(s) and avail themselves of filings and information that may be accessed at sec.gov or pink sheets or other electronic medium, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (e) consulting investment guides at sec.gov and finra.com pertaining to the risks of investing in penny stocks. In the end result, Readers must evaluate and bear all the risks associated with the Information, including reliance on its accuracy, completeness or usefulness. In all instances, the Reader should conduct further inquiry into the Profiled Company and its securities. The Profiled Companies are subject to possible risks, including but not limited to: (a) the Information pertains to penny stocks that are subject to the SEC's penny stock rules and commonly involve a high degree of risk that may result in the loss of some or all of an investment in the Profiled Company's securities; (b) the Issuer's penny stock may be thinly traded, which may lead to difficulties of selling its securities; (c) the SEC reporting issuer may be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports) or the Pink Sheet quoted company may be delinquent in its Pink Sheet reporting obligations as indicated by Pink Sheets New Service's posting a negative "sign" pertaining to the Issuer at pink sheets, as follows: (i) "Limited Information" for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) "Pink Sheets - No Information", which indicates companies that are unable or unwilling to provide disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) "Caveat Emptor", signifying "Buyer Beware" that there is a public interest concern associated with a company's illegal spam campaign, questionable stock promotion, known investigation of a company's fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions; (d) whether the Issuer is a development stage company with little or no operations, the securities of which should be considered extremely speculative for investment purposes; (e) OTC's selling of an Issuer's securities may cause its stock price to significantly decline, especially when such securities are thinly traded; (f) many companies that have their securities quoted on the OTCBB or Pink Sheets (as well as even Exchange listed companies) have been negatively affected by the current economic downturn and lack of adequate financing to meet their operational goals or expansion plans; (g) any percentage gain from the previous day close presented on our website at is not and should not be construed as any indication whatsoever of the future stock price of an Issuer's securities or its operational results; (h) many of the energy related and other Profiled Companies are subject to increasing environmental and other governmental regulations, which subjects them to significant costs and possible fines and liabilities for failure to comply with applicable state and federal statutes; (i) OTC may receive compensation in shares of the Issuer and it or its associates, affiliated entities, officers, directors or immediate family members may sell the Shares immediately upon their receipt as well as during the dissemination of such Information or within hours, days, weeks or months thereafter, or at any time; as a result, OTC's selling activities may cause significant volatility in the Issuer's stock price and/or significantly depress the Issuer's stock price; (j) OTC may buy and sell the Shares in the open market before, during or after the dissemination of the Information or at any time, which may cause significant volatility including drops in the price of the Issuer's stock price and/or significantly depress the Issuer's stock price; (k) future success of many OTCBB and Pink Sheet quoted Issuers is dependent upon receiving adequate financing or raising sufficient capital, which they may be unable to obtain; (l) there is an inherent and actual conflict of interest that exists between our Readers' interests and OTC's interests because OTC's owners, OTC: (i) receive the Shares as compensation for disseminating the Information and thereafter sell those Shares at any time for monetary gain, including at the same time the Information is being disseminated or shortly thereafter or at any time; and (ii) buys and sells the Profiled Company's shares in the open market at the same time or before the Information is being disseminated or shortly after the dissemination of the Information or at any time; (m) we do not receive any direct verification from the Issuer regarding the Information; (n) a third party shareholder may have a potential or actual conflict of interest in paying OTC for the dissemination of the publication while still holding the Issuer's shares of common stock that he or she may sell after the third party shareholder has paid OTC with his or her shares; (o) the Information should not be interpreted in any shape, form or manner whatsoever as an indication of the Issuer's future stock price or future financial performance since, among other reasons, such "comparison" companies are listed on exchanges (i.e., the New York Stock Exchange) and trade at stock prices that are thousands of percent higher than the companies we profile; and (p) Readers may encounter difficulties determining what information contained in our publications is material or non-material making it all the more imperative that they conduct further investigation of the Profiled Company and its securities ; and (q) OTC hires third party Service Providers to electronically disseminate live news regarding the Issuer, information which we do not independently provide to the Service Provider or verify and upon which we have no control over. We pay cash consideration to the Service Providers; no securities compensation is paid to the Service Providers; and (r) our employees post messages on their individual message boards as a method of disseminating the Information on behalf of our Issuer clients which should never be used as a means of conducting analysis into the Issuer and should only be used as a starting point to obtain the names of pink sheet or OTC Bulletin Board. Please be advised that OTCtipReporter.com has NOT been compensated?to profile XUII. We Own NO Shares. | Source: http://newsletter.hotstocked.com/newsletters/view/_WINDOWS-1252_Q_XUII_-_WARNING_RISKY_Bounce____WINDOWS-1252_Q_Play_watch_Wednesday-1062972
macys jcpenney toys r us toys r us kohls target target
![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 25-Jul-2013
Share ] 
By Laura Jones: She blogs about and reviews video games to recapture her misspent youth, growing up gaming on hand-me-down consoles and cast-off computers with three siblings fighting over the controllers and helping each other beat Bosses. Read her posts and watch her video game reviews here and connect with her on Twitter and at Google+.
According to Hollywood news website The Wrap, Sony is developing the racing video game franchise Gran Turismo into an action movie. Fifty Shades of Grey producers Mike De Luca and Dana Brunetti are steering the project based on the PlayStation game franchise by Kazunori Yamauchi and Polyphony Studios. Sony executives Elizabeth Cantillon, DeVon Franklin and Hannah Minghella are also involved.